You are here

For the Second Time This Year, Pfizer Hikes Drug Prices

The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year.

The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year.

The price for Pfizer’s lung-cancer treatment Xalkori, its blood-pressure pills Norvasc, and its pain capsules Lyrica will be going up, along with about 40 other of the company’s drugs, the Wall Street Journal reports. Pfizer, the world’s biggest drug company by sales, defends its actions by saying that it frequently sells its drugs at discount and, anyway, it is not responsible for what patients must pay in co-pays or out-of-pocket costs.

The company said in a statement: “The list price remains unchanged for the majority of our medicines. We are modifying prices for about 10% of our medicines, including some instances where we’re decreasing the price.”

The WSJ reports that many of the increases “lift the list prices by 9.4% and by double-digit percentages for the year overall.”

Source: Wall Street Journal

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial